You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

ALORA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Alora, and when can generic versions of Alora launch?

Alora is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in ALORA is estradiol. There are seventy-five drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the estradiol profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Alora

A generic version of ALORA was approved as estradiol by BARR LABS INC on October 22nd, 1997.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ALORA?
  • What are the global sales for ALORA?
  • What is Average Wholesale Price for ALORA?
Summary for ALORA
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 109
Patent Applications: 4,063
Drug Prices: Drug price information for ALORA
What excipients (inactive ingredients) are in ALORA?ALORA excipients list
DailyMed Link:ALORA at DailyMed
Drug patent expirations by year for ALORA
Drug Prices for ALORA

See drug prices for ALORA

US Patents and Regulatory Information for ALORA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-004 Apr 5, 2002 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-003 Dec 20, 1996 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-001 Dec 20, 1996 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-002 Dec 20, 1996 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ALORA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-002 Dec 20, 1996 ⤷  Sign Up ⤷  Sign Up
Abbvie ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-004 Apr 5, 2002 ⤷  Sign Up ⤷  Sign Up
Abbvie ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-001 Dec 20, 1996 ⤷  Sign Up ⤷  Sign Up
Abbvie ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-002 Dec 20, 1996 ⤷  Sign Up ⤷  Sign Up
Abbvie ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-003 Dec 20, 1996 ⤷  Sign Up ⤷  Sign Up
Abbvie ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-004 Apr 5, 2002 ⤷  Sign Up ⤷  Sign Up
Abbvie ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-002 Dec 20, 1996 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ALORA

See the table below for patents covering ALORA around the world.

Country Patent Number Title Estimated Expiration
Australia 651165 ⤷  Sign Up
Australia 656755 ⤷  Sign Up
Australia 9141391 ⤷  Sign Up
Hong Kong 1013790 ⤷  Sign Up
Germany 69129632 ⤷  Sign Up
South Korea 100200002 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 9210231 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ALORA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1453521 300814 Netherlands ⤷  Sign Up PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
0398460 12/2004 Austria ⤷  Sign Up PRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211
0136011 2000C/027 Belgium ⤷  Sign Up PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
0136011 99C0003 Belgium ⤷  Sign Up PRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306
0770388 PA2009004,C0770388 Lithuania ⤷  Sign Up PRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
0398460 04C0022 France ⤷  Sign Up PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211
2782584 C202130068 Spain ⤷  Sign Up PRODUCT NAME: COMPOSICION QUE CONTIENE ESTRADIOL (17BETA-ESTRADIOL), INCLUYENDO EN FORMA DE HEMIHIDRATO, Y PROGESTERONA; NATIONAL AUTHORISATION NUMBER: 85988-NL/H/4994/001/DC; DATE OF AUTHORISATION: 20210528; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): BE582231; DATE OF FIRST AUTHORISATION IN EEA: 20210406
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.